IWG 2016 and the National Institute on Aging and Alzheimer’s Association (NIA-AA) research framework are aligned on the key issue that although AD is currently defined as a biological event throughout the course, the combination of abnormal β-amyloid (Aβ) and tau biomarkers is conclusive enough to define AD regardless of cognitive symptoms (Jack et al., 2018). The gene discussed is MAPT; the disease is Alzheimer disease.